No Data
Edit (301580): Q3 growth slows down, actively layout on the growth track.
Investment Highlights: In the first three quarters of 2024, the company achieved revenue of 0.64 billion yuan, a year-on-year increase of 14%; net income attributable to mother of 0.11 billion yuan, a year-on-year increase of 13%; non-recurring net income attributable to mother of 110 million yuan, a year-on-year increase of 2.
Editt: Third quarter report 2024
AiDiTe (301580.SZ): The net income for the first three quarters was 0.111 billion yuan, an increase of 12.71% year-on-year.
Aidite (301580.SZ) announced on October 27th that it achieved revenue of 0.641 billion yuan in the first three quarters of 2024, a year-on-year increase of 14.09%; net income attributable to shareholders of the listed company was 0.111 billion yuan, a year-on-year increase of 12.71%, with a basic earnings per share of 1.75 yuan.
Edut (301580.SZ) released its performance for the first three quarters, with a net income of 0.111 billion yuan, a year-on-year increase of 12.71%.
Aidite (301580.SZ) released the third quarter report for 2024, with revenue for the first three quarters of the company reaching 6.4...
Aidite (301580.SZ): As of the end of 2023, the proportion of the R&D team reached 14.64%, and R&D innovation investment has been increasing year by year.
Gelonghui October 14th| Edute (301580.SZ) stated on the investor interaction platform that the company has been shortlisted in the sixth batch of national specialized, special and new "little giant" enterprise public announcement list, and will be publicly announced in early September 2024. The company focuses on casting expertise, supporting strong industries, and winning markets through innovation. By the end of 2023, the proportion of the R&D team is 14.64%, and R&D innovation investment has increased year by year. After more than 10 years of technological accumulation and product iteration, since 2021, the company has successively won the first prize of the Beijing Science and Technology Award, the Geneva Invention Gold Award, and other honors, and obtained the national key R&D program "Diagnosis".
Aidite (301580.SZ): Zirconia material is currently the preferred material for clinical oral restoration due to its excellent performance.
On September 29, GeLongHui reported that AideTe (301580.SZ) stated at an investor relations event that zirconia material is the preferred material for clinical oral restoration due to its excellent performance.
No Data
No Data